

N- α -Fmoc-Lys(N- ϵ -tBoc) (1)

N- α -Fmoc-lysine (2)

Fig. 1a




Fig. 1b




Fig. 1c
N- ϵ -biotinyl lysine
N- α -Fmoc-Lys(N- ϵ -biotin)

Fig. 2a






Fig. 2b



sample 8320



sample 8242





Fig. 3a-1

sample 8243

optical density



sample 8318

optical density





Fig. 3a-2

sample 8320



sample 8326





Fig. 3b-1

sample 8242



sample 8243





Fig. 3b-2

sample 8243

optical density




coating concentration ($\mu\text{g/ml}$)

— HCV peptide XVIBIO + HCV peptide XVI

sample 8318

optical density




coating concentration ($\mu\text{g/ml}$)

— HCV peptide XVIBIO + HCV peptide XVI

Fig. 3c-1

sample 8326

optical density



sample 8242

optical density





Fig. 3c-2

HCV peptide II-BIO



HCV peptide XI-BIO




Fig. 4a

HCV peptide XVI-BIO




Fig. 4b

Fig. 5a





Fig. 5b



N-terminally biotinylated
TM peptide

C-terminally biotinylated
TM peptide

Fig. 6a-1




Fig. 6a-2




Fig. 6a-3




Fig. 6a-4




Fig. 6a-5




Fig. 6b-1




Fig. 6b-2




Fig. 6b-3




Fig. 6b-4




Fig. 6b-5




Fig. 6c-1




Fig. 6c-2




Fig. 6c-3




Fig. 6c-4




Fig. 6c-5




Fig. 6c-6




Fig. 6c-7




Fig. 6c-8




Fig. 6c-9




Fig. 6c-10




Fig. 7a-1

<u>Peptide I</u>	MSTIPKPQRKTKRNTNRRPQ PQRKTKRNTNRRPQDVKFPQ	(SEQ ID NO:453)
<u>Peptide II</u>	RNTNRRPQDVKFPGGGQIVG	(SEQ ID NO:454)
<u>Peptide III</u>		(SEQ ID NO:455)
<u>Peptide I</u>		
(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)
(178) MSTIPKPQR	(184) PQRKTKRNT	(190) RNTNRRPQD
(179) STIPKPQRK	(185) QRKTKRNTN	(191) NTNRRPQDV
(180) TIPKPQRKT	(186) RKTKRNTNR	(192) TNRNPQDVK
(181) IPKPQRKTK	(187) KTKRNTNRR	(193) NRPQDVKF
(182) PKPQRKTKR	(188) TKRNTNRRP	(194) RPQDVKF
(183) KPQRTKRN	(189) KRNTNRRPQ	(195) RPQDVKFPG
(184) PQRKTKRNT	(190) RNTNRRPQD	(196) PQDVKFPGG
(185) QRKTKRNTN	(191) NTNRRPQDV	(197) QDVKFPGGG
(186) RKTKRNTNR	(192) TNRRPQDVK	(198) DVKFPGGGQ
(187) KTKRNTNRR	(193) NRRPQDVKF	(199) VKFPGGGQI
(188) TKRNTNRRP	(194) RRPODVKF	(200) KFPGGGQIV
(189) KRNTNRRPQ	(195) RPQDVKFPG	(201) FPFGGGQIVG

Fig. 7a-2

Core 5	(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)
Peptide IV	(202) PGGGQIVGGG	(214) LPRRGPRLG	(226) TRKTSERSQ
Peptide V	(203) GGGQIVGGV	(215) PRRGPRLGV	(227) RKT SERSQP
Peptide VI	(204) GGQIVGGVY	(216) RRGPRLGVR	(228) KTSERSQPR
	(205) GQIVGGVYL	(217) RGPRLGVRRA	(229) TSERSQPRG
	(206) QIVGGVYLL	(218) GPRLGVRAT	(230) SERSQPRGR
	(207) IVGGVYLLP	(219) PRLGVRA TR	(231) ERSQPRGR
	(208) VGGVYLLPR	(220) RLGVRA TRK	(232) RSQPRGRQQ
	(209) GG'VYLLP RR	(221) LGVRATRKT	(233) SQPRGRQQP
	(210) GVYLLP RRG	(222) GVRATRKT S	(234) QPRGRQQPI
	(211) VYLLP RRG P	(223) VRATRKTSE	(235) PRGRRQQPI P
	(212) YLLP RRG P R	(224) RATRKT SER	(236) RGRRQQPI K
	(213) LLPRRG PRL	(225) ATRKT SERS	(237) GRRQPI PKV

Core 5	Peptide IV	Peptide V	Peptides VI
(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)
(202) PGGGQIVGGG	(214) LPRRGPRLG	(226) TRKTSERSQ	(238) RRQPIPKVVR
(203) GGGQIVGGV	(215) PRRGPRLGV	(227) RKT SERSQP	(239) RQPIPKVRR
(204) GGQIVGGVY	(216) RRGPRLGVR	(228) KTSERSQPR	(240) QPIPKVRRP
(205) GQIVGGVYL	(217) RGPRLGVRRA	(229) TSERSQPRG	(241) PIPKVRRPE
(206) QIVGGVYLL	(218) GPRLGVRAT	(230) SERSQPRGR	(242) IPKVRRPEG
(207) IVGGVYLLP	(219) PRLGVRA TR	(231) ERSQPRGR	(243) PKVRRPEGR
(208) VGGVYLLPR	(220) RLGVRA TRK	(232) RSQPRGRQQ	(244) KVRRPEGRT
(209) GG'VYLLP RR	(221) LGVRATRKT	(233) SQPRGRQQP	(245) VRRPEGRTW
(210) GVYLLP RRG	(222) GVRATRKT S	(234) QPRGRQQPI	(246) RRPEGRTWA
(211) VYLLP RRG P	(223) VRATRKTSE	(235) PRGRRQQPI P	(247) RPEGRTWAQ
(212) YLLP RRG P R	(224) RATRKT SER	(236) RGRRQQPI K	(248) PEGRTWAQP
(213) LLPRRG PRL	(225) ATRKT SERS	(237) GRRQPI PKV	(249) EGRTWAQPG

Fig. 7a-3




Fig. 7b-1

	<u>HCV1</u>	<u>HCV2</u>	<u>HCV3</u>	<u>HCV4</u>	<u>HCV5</u>	<u>HCV6</u>	<u>HCV1</u>	<u>HCV2</u>	<u>HCV3</u>	<u>HCV4</u>	<u>HCV5</u>	<u>HCV6</u>	
HCV1	LSGK(KPAIIPDREVLYREFDE	(SEQ ID NO:460)					(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)	
HCV2	IIPDREVLYREFDEMEEC	SQ	(SEQ ID NO:460)				(258) LSGK(KPAIIPDREVLYREFDE	(276 DEMEECSQH	(282 SQHL	(284 HLPYIEQ	(288 IEQGMM	(288 IEQGMM	
HCV3	VLYREFDEMEEC	SQHL	PIYE	(SEQ ID NO:462)			(259) SGKPAIIPD	(265) IPDREVLYR	(271 LYREFDEME	(277 EMEEC	(283 SQHL	(289 EQGMM	(289 EQGMM
HCV4	DEMEECSQHL	PIYE	(SEQ ID NO:463)				(260) GKPAAIIPDR	(266) PDR	(272 YREFDEME	(278 MEECSQHLP	(284 HLPYIEQGM	(290 QGMM	(290 QGMM
HCV5	SQHL	PIYE	EQGMM	LAEQFKQK	(SEQ ID NO:464)		(261) KPAIIPDRE	(267) DREVLYREF	(273) REFDEME	(279 EEC	(285 LPYIEQGMM	(291 GMMLA	(291 GMMLA
HCV6	EQGMM	LAEQFKQK	(SEQ ID NO:465)				(262) PAIIIPDREV	(268) REVLYREFD	(274) FDEMEECS	(280 EC	(286 PYIEQGMM	(292 MMMLAEQF	(292 MMMLAEQF
							(263) AIIIPDREVL	(269) EVLYREFDE	(275) FDEMEECS	(281 CSQHL	(287 YIEQGMM	(293 MLAEQF	(293 MLAEQF
							(264) IIIPDREVL	(270) VLYREFDE	(276) DEMEECSQH	(282 SQHL	(288 IEQGMM	(294 LAEQF	(294 LAEQF
							(265) IIPDREVL	(271 LYREFDEME	(277 EMEEC	(283 SQHL	(289 EQGMM	(295 AEQF	(295 AEQF
							(266) PDREVLYR	(272 YREFDEME	(278) MEECSQHLP	(284 HLPYIEQGM	(290 QGMM	(296 EQFKQ	(296 EQFKQ
							(267) DREVLYREF	(273 REFDEME	(279) EEC	(285 LPYIEQGMM	(291 GMMLAEQF	(297 QFKQ	(297 QFKQ
							(268) REVLYREFD	(274 FDEMEECS	(280) EC	(286 PYIEQGMM	(292 MMMLAEQFK	(298 FKQKAL	(298 FKQKAL
							(269) EVLYREFDE	(275 FDEMEECSQ	(281 CSQHL	(287 YIEQGMM	(293 MLLAEQFK	(299 KQKAL	(299 KQKAL

Fig. 7b-2

HCV7
HCV8
HCV9

LAEQFKQKALGILLQTA
SEQ ID NO:466)
LQKALGLLQTA
SEQ ID NO:467)
LQTASRQAEVIA
SEQ ID NO:468)

HCV7

HCV8

HCV9

(SEQ ID NO:) (SEQ ID NO:) (SEQ ID NO:)
(294) LAEQFKQKA (300) QKALGLLQT (306) LQTASRQAE
(295) AEQFKQKAL (301) KALGLLQTA (307) QTASRQAEV
(296) EQFKQKALG (302) ALGLLQTAS (308) TASRQAEVI
(297) QFKQKALGL (303) LGILLQTA
SR (309) ASRQAEVIA
(298) FKQKALGLL (304) GLLQTASRQ (310) SRQAEVIAP
(299) KQKALGLLQ (305) LLQTA
SRQAEVIA
(300) QKALGLLQT (306) LQTASRQAE (312) QAEVIA
PAV
(301) KALGLLQTA (307) QTASRQAEV (313) AEVIA
PAVQ
(302) ALGLLQTAS (308) TASRQAEVI (314) EVIAPAVQT
(303) LGLLQTA
SR (309) ASRQAEVIA (315) VIAPAVQTN
(304) GLLQTASRQ (310) SRQAEVIAP (316) IAPAVQTNW
(305) LLQTA
SRQAEVIA
PA (311) APAVQTNWQ
(317) APAVQTNWQ

Fig. 7b-3




Fig. 7c-1

<u>NS5 - 21</u>	<u>NS5 - 23</u>	<u>NS5 - 25</u>	<u>NS5 - 27</u>	<u>NS5 - 29</u>	<u>NS5 - 21</u>	<u>NS5 - 23</u>	<u>NS5 - 25</u>	<u>NS5 - 27</u>	<u>NS5 - 29</u>
NS5 - 21 GNITTRYSENKVVILDSEFDP	(SEQ ID NO:469)				SEQ ID NO:				
NS5 - 23 VILDSEFDPLVAAEEDEREISV	(SEQ ID NO:470)				330VILDSFDPL 330VILDSFDPL 330VILDSFDPL 330VILDSFDPL 330VILDSFDPL				
NS5 - 25	EDEREISVPAEILRKSRFA	(SEQ ID NO:471)			331ITRYESEN	331ITRYESEN	331ITRYESEN	331ITRYESEN	331ITRYESEN
NS5 - 27	(SEQ ID NO:472) LRKSRFAQALPVWARP DYN				332ITRYESEN K				
NS5 - 29	(SEQ ID NO:473) VWARPDYNPPVWARP DYN				333TRYESEN KV				
					334YESENKVV	334YESENKVV	334YESENKVV	334YESENKVV	334YESENKVV
					FDPLVAAEED	FDPLVAAEED	FDPLVAAEED	FDPLVAAEED	FDPLVAAEED
					347ITSVPAEILR	347ITSVPAEILR	347ITSVPAEILR	347ITSVPAEILR	347ITSVPAEILR
					348SVPAEILRK	348SVPAEILRK	348SVPAEILRK	348SVPAEILRK	348SVPAEILRK
					349VPAEILRK S				
					350PAEILRKSR	350PAEILRKSR	350PAEILRKSR	350PAEILRKSR	350PAEILRKSR
					351AEIELRKSR	351AEIELRKSR	351AEIELRKSR	351AEIELRKSR	351AEIELRKSR
					352EILRKSRRF	352EILRKSRRF	352EILRKSRRF	352EILRKSRRF	352EILRKSRRF
					353ILRKSRFA	353ILRKSRFA	353ILRKSRFA	353ILRKSRFA	353ILRKSRFA

Fig. 7c-2

NS5-31
NS5-33

ETWKKPDYEPVVHGCPLPP (SEQ ID NO:474)
(SEQ ID NO:475) VHGCPLPPPSSPPVPPRKK

NS5-31
(SEQ ID NO:)

NS5-33
(SEQ ID NO:)

378	ETWKKPDYE	390	VHGCPLPPK
379	TWKKPDYEP	391	HGCPLPPKS
380	WKKPDYEP	392	GCPPLPPKSP
381	KKPDYEP	393	CPLPPKSPPP
382	KPDYEP	394	PLPPKSPPPV
383	PDYEP	395	LPPPKSPPPV
384	DYEPP	396	PPPKSPPPPV
385	YEPPVVHG	397	PPKSPPVPP
386	EPPVVHGCP	398	PKSPPVPPP
387	PPVVHGCP	399	KSPPVPPPR
388	PVVHGCP	400	SPPVPPPRK
389	VVHGCP	401	PPVPPPRKK

Fig. 7c-3




Fig. 7c-4





Fig. 8



- a: High intensity control
- b: Low intensity control
- c: Medium intensity control
- d: Peptide XXg-1, unbiotinylated
- e: Peptide XXg-2, unbiotinylated
- f: Biotinylated peptide XXg-1: streptavidin complex
- g: Biotinylated peptide XXg-2: streptavidin complex

Fig. 9




Fig. 10




Fig. 11

Peptide	Sequence
NS4-a	GALVAFKIMSGEVVPSTEDLV (SEQ ID NO: 445)
NS4-b	VPSTEDL VNLLPAILSPGAL (SEQ ID NO: 446)
NS4-c	AILSPGALVVGVVCAAIIIRR (SEQ ID NO: 447)
NS4-d	(SEQ ID NO: 448) VCAAILRRHVGPGEGAVQWM
NS4-e	(SEQ ID NO: 449) GEGAVQWMNRLIAFASRGNH

Fig. 12

(SEQ ID NO:)	Peptide	Amino Acid Sequence
Epi-152 (450)	Bio- G G - I P D R E V L Y R G K P D Y E P P V G G R R P Q D V K F P	NS5 epitope 5 Core epitope 2
Epi-33B3A (451)	Bio- G G - W A R P D Y N P P G G Q F K Q K A L G L G S G V Y L L P R R G	NS4 epitope 3B NS4 epitope 3A
Epi-4B2A6 (452)	Bio- G G - R G R R Q P I P K G G S Q H L P Y I E Q S G P V V H G C P L P	NS5 epitope 6 NS4 epitope 2A Core epitope 4B

Fig. 13




Fig. 14a

Fig. 146




Fig. 14c




Fig. 14d




Fig. 15




Fig. 16A






Fig. 16B

Cleavage and side-chain deprotection



Oxidation and dimerization





Fig. 17A


	PRE- IMMUNE 13.01.92	FIRST BLEEDING 07.04.92	BLANK					
RABBIT No	325	326	327	328	325	326	327	328



RABBIT 325, 326: XXb-2-MAP
RABBIT 327, 328: XXg-2-MAP

Fig. 17B

	PRE- IMMUNE 13.01.92	FIRST BLEEDING 07.04.92	BLANK
RABBIT No	325	326	327



RABBIT 325, 326: XXb-2-MAP
RABBIT 327, 328: XXg-2-MAP

BBI ANTI-HTLV I/II MIXED TITER PERFORMANCE PANEL PRP302




Fig. 18

BLOOD DONOR SERA